Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease
Objective: To compare and contrast nilotinib and vodobatinib regarding efficacy, brain penetration, and safety. Background: Preclinical evidence suggests that c-Abl is critical for pathogenesis of…Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort
Objective: To examine 2-year longitudinal change in clinical, dopamine transporter (DAT) imaging and biofluid biomarkers in non-manifesting carriers (NMCs) of LRRK2 G2019S versus healthy controls…Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease: the PD COMM randomised controlled trial.
Objective: To evaluate the clinical effectiveness of two speech and language therapy (SLT) approaches compared to no SLT (control) for people with Parkinson’s disease (PD).…Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report
Objective: To report the use of levodopa-carbidopa intestinal gel (LCIG) as an additional therapy for the treatment of motor fluctuations in a patient with advanced…Feasibility of using mobile technology for aerobic exercise management in people with Parkinson’s disease
Objective: To examine the usability of a smartwatch heart rate monitor for monitoring aerobic exercise compliance during a 6-month brisk walking program, and to evaluate…SelfCog®: a digitized cognitive battery to classify Parkinson disease (PD) patients with or without Mild Cognitive Impairment (MCI)
Objective: We tested the performance of the SelfCog® to classify PD patients as MCI. Background: MCI is a strong risk factor of dementia in PD…Genetics Of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) : Genetics of Juvenile, Young and Early Onset Parkinson’s Disease
Objective: To determine the genetic and demographic patterns of juvenile-onset (JOPD, <20 years), young-onset (YOPD, 20-40 years), and early onset (EOPD, 40-50 years) Parkinson's disease…Clinical characteristics in de-novo PD patients with reversible vs. progressive cognitive dysfunction during long-term follow-up
Objective: To compare clinical and imaging features in de-novo Parkinson’s disease (PD) with stable, remitting, and non-remitting cognition over 5 years follow-up. Background: Mild cognitive…The Lion’s tail family: A Bavarian multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia
Objective: To characterize a North-Bavarian (Lion’s tail region) six-generation pedigree, including neuropathologically confirmed multiple system atrophy and Parkinson’s disease with dementia. Background: Multiple system atrophy…
- « Previous Page
- 1
- …
- 236
- 237
- 238
- 239
- 240
- …
- 338
- Next Page »